Bone Biologics (OTC:BBLG – Get Free Report) is one of 129 publicly-traded companies in the “Medical Devices” industry, but how does it weigh in compared to its peers? We will compare Bone Biologics to related companies based on the strength of its risk, valuation, dividends, earnings, profitability, analyst recommendations and institutional ownership.
Volatility and Risk
Bone Biologics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Bone Biologics’ peers have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Bone Biologics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
| Bone Biologics Competitors | 199 | 1058 | 1175 | 86 | 2.46 |
Insider & Institutional Ownership
25.9% of shares of all “Medical Devices” companies are owned by institutional investors. 7.9% of Bone Biologics shares are owned by insiders. Comparatively, 25.9% of shares of all “Medical Devices” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Bone Biologics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bone Biologics | N/A | -123.44% | -82.64% |
| Bone Biologics Competitors | -62.27% | -37.50% | -15.39% |
Valuation and Earnings
This table compares Bone Biologics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Bone Biologics | N/A | -$1.49 million | -0.08 |
| Bone Biologics Competitors | $502.26 million | $19.38 million | 77.49 |
Bone Biologics’ peers have higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Bone Biologics peers beat Bone Biologics on 9 of the 13 factors compared.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
